9.3 Avastin
Summary
Bevacizumab (Avastin; Genentech, Inc.; South San Francisco, CA) is a full-length murine monoclonal, anti-VEGF antibody. This VEGF-specific inhibitor of angiogenesis is approved for several types of cancer including: colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.
Quiz Module 9.3
Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account
To validate your answers and keep track of your progress please sign in or register a new account
1. Bevacizumab is currently approved by the FDA for the treatment of all of the diseases below except:
2. What study will be comparing the efficacy and safety of bevacizumab, ranibizumab, and aflibercept?
3. What is one of the drawbacks to the use of bevacizumab for DR and DME?
4. True or False: There are currently numerous large-scale clinical results to support the use of bevacizumab for the treatment of DME and PDR.